07 Oct 2020

Interview with Lisa Anson in The Sunday Times

14 Sep 2020

Trinity Delta Research Report Published

09 Sep 2020

Redx announces new research collaboration with Jazz Pharmaceuticals to discover and develop two targeted cancer therapies

20 Aug 2020

Further information regarding the offer to purchase shares by Redmile Group LLC

05 Aug 2020

Appointment of Non-Executive Director and changes to Board committees

04 Aug 2020

Redx signs out licensing agreement with AstraZeneca

20 Jul 2020

Result of General Meeting

30 Jun 2020

Proposed financing of $30 million via issue of convertible loan notes and share subscription and notice of General Meeting

30 Jun 2020

Interim results for the six months ended 31 March 2020

30 Jun 2020

New All Employee Share Option Scheme and Grant of Options

20 May 2020

Change of Adviser

18 May 2020

Appointment of Non-Executive Director with Deep Experience of the Biotechnology Industry and Capital Markets

23 Apr 2020

Result of Annual General Meeting and operational update

31 Mar 2020

Further information for shareholders regarding attendance at the Company’s Annual General Meeting on 23 April 2020

30 Mar 2020

Redx Redmile Loan announcement

11 Mar 2020

Final Audited Results for the Year Ended 30 September 2019 and operational update

28 Feb 2020

Redx agrees funding from Redmile Group, LLC & Sofinnova Partners

28 Feb 2020

Termination of discussions with Yesod Bio-Sciences Limited (“Yesod”)

14 Feb 2020

Further statement re Rule 2.6 Extension

28 Jan 2020

Statement re Rule 2.6 Extension

23 Jan 2020

Result of General Meeting

09 Jan 2020

Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis

03 Jan 2020

Shareholder Circular – Proposed Capitalisation of Loan

31 Dec 2019

Redx Pharma plc – Loan Capitalisation, GM Notice and Possible Offer

19 Nov 2019

Redx Pharma and Medicines Discovery Catapult awarded grant for biomarker project which aims to accelerate therapeutic development for idiopathic pulmonary fibrosis

23 Sep 2019

Poster presentation at ERS Congress highlights RXC006 as a novel and promising drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF)

19 Aug 2019

First Cohort of Patients Successfully Dosed in RXC004 Phase 1/2 Study; Second Cohort Enrolment Has Now Begun

10 Jul 2019

Redx announces sale of its pan-RAF inhibitor programme to Jazz Pharmaceuticals

10 Jun 2019

Interim Results for the six months ended 31 March 2019

10 Jun 2019

Short-term Debt Funding Secured

03 May 2019

Update on Plans to Strengthen Balance Sheet

29 Mar 2019

Redx Pharma to present two posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting

28 Feb 2019

Issue of Warrants and Change to Lease Agreement

14 Feb 2019

Redx announces directorate update and grant of options

12 Feb 2019

New in vivo data suggests ROCK2 has broad potential in fibrosis

06 Feb 2019

Redx confirms receipt of outstanding loan

31 Jan 2019

Deinove return rights to Redx’s Anti-infective Programme

23 Jan 2019

Results of Annual General Meeting

21 Jan 2019

Redx to resume RXC004 clinical trial programme

03 Jan 2019

Redx to present at 2019 Biotech Showcase event in San Francisco

02 Jan 2019

Annual Report and Accounts for the year ended 30 September 2018

30 Nov 2018

First RXC006 data suggests it has great potential for the treatment of fibrosis

19 Nov 2018

Final Audited Results for the Year Ended 30 September 2018

19 Nov 2018

Redx further strengthens Management Team and Board with appointment of Dr James Mead as CFO

14 Nov 2018

Redx Pharma announces new drug development candidate for fibrosis

05 Nov 2018

Preclinical data evaluating RXC004 presented at the NCRI cancer conference

31 Oct 2018

Preliminary Results – Analysts’ Meeting and Webcast on Monday, 19 November 2018

31 Oct 2018

Notice of Results

29 Oct 2018

REDX Pharma notes election of Lisa Anson to UK BIA Board of Directors

26 Oct 2018

Redx announces details from the ROCK2 inhibitor poster presented at the ASN Kidney Week 2018 in San Diego

22 Oct 2018

Redx ROCK2 inhibitors poster to be presented at the ASN Kidney Week 2018 in San Diego

04 Sep 2018

Redx Pharma Announces Way Forward For RXC004

04 Jun 2018

Directorate Update and Grant of Options

30 May 2018

Interim Results Announced

24 Apr 2018

Redx Appoints Senior AstraZeneca Executive as CEO

29 Mar 2018

RXC004 Clinical Trial Update

22 Mar 2018

Redx Pharma signs option and licence agreement for its anti-infective programme with Deinove

15 Mar 2018

Redx Pharma to present poster at prestigious American Association for Cancer Research Annual Meeting

06 Feb 2018

Redx Pharma Announces First Patient Dosed in Phase 1/2a

22 Jan 2018

Redx Pharma appoints chief medical officer who will oversee launch of phase I clinical trial of new cancer drug

20 Dec 2017

Final Results for the Year Ended 30 September 2017

06 Nov 2017

Redx Provides a Strategic Update and Announces that Trading is to recommence in its Shares

02 Nov 2017

The Joint Administrators’ Final Report for the period 24 May 2017 to 2 November 2017

13 Oct 2017

Permission granted for distribution to Unsecured Creditors

31 Aug 2017

Redx to present new scientific data at ESMO 2017

24 May 2017

In Administration

17 May 2017

Interim Results for the six months ended 31 March 2017

15 May 2017

Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia

20 Apr 2017

Appointment of Chairman

10 Apr 2017

Redx Pharma presents data in oncology and fibrosis at two key scientific congresses

30 Mar 2017

Redx Pharma awarded US$1 million grant by CARB-X

21 Mar 2017

Final Results for the year ended 30 September 2016

03 Mar 2017

Redx to present new scientific data at AACR 2017

02 Mar 2017

Nationwide search begins for science’s inspirational business leaders

27 Jan 2017

Redx outlines growing opportunity for Porcupine inhibitors

06 Dec 2016

Pre-clinical profile of reversible BTK inhibitor RXC005 presented at ASH 2016

30 Nov 2016

Pre-clinical profile of Porcupine inhibitor RXC004 presented at EORTC-NCI-AACR 2016

14 Nov 2016

Redx Pharma in the running for prestigious North of England awards

10 Nov 2016

Redx backs global AMR event

04 Nov 2016

Redx to present pre-clinical profile of its reversible BTK inhibitor at ASH 2016

25 Oct 2016

Redx supports young scientists in Staffordshire University’s GradEX exhibition

25 Oct 2016

Redx to present Preclinical Data on Novel Bacterial Topoisomerase Inhibitors at ASM Microbe 2016 Conference

20 Oct 2016

Development candidate chosen for leukaemia program

27 Sep 2016

Discovery of breakthrough antibiotic compounds

19 Sep 2016

Redx confirms potential role for Porcupine inhibitor in cancer immunotherapy

08 Sep 2016

Board and Senior Management Changes

06 Sep 2016

Supply contract agreed with Quay Pharma for expected clinical trial of Porcupine inhibitor

10 Jun 2016

Redx backs North of England biotech focus

06 Jun 2016

World leaders in biotech to hear from Northern Powerhouse

24 May 2016

Interim Results

24 May 2016

Proof of concept with key oncology lead

19 May 2016

O’Neill signs off with powerful plan to tackle superbugs

09 May 2016

Board appointment

16 Apr 2016

Redx Pharma to present at the Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans on 20 April

14 Apr 2016

Redx Pharma Plc set for new HQ at Alderley Park

12 Apr 2016

Redx backs key AMR conference

24 Mar 2016

Placing to Raise £10 Million

26 Feb 2016

Redx honoured at Institute of Directors Awards

24 Feb 2016

AGM Statement – Sixth proof of concept – Potential new treatment for gonorrhoea

03 Feb 2016

World Cancer Day 2016

21 Jan 2016

Redx joins global pharma call on governments to help tackle AMR crisis

20 Jan 2016

Final Results for the year ended 30 September 2015

01 Jan 2016

Appointment of Non-Executive Director

03 Dec 2015

Redx Pharma announces fourth drug development candidate

27 Nov 2015

Redx Pharma wins Deal of the Year at Bionow Awards

10 Nov 2015

BioInfect Conference – Redx joins industry leaders to combat one of the biggest threats to global health

05 Nov 2015

Senior management appointments

28 Oct 2015

Millions of wasted prescriptions adding to superbug threat, warns O’Neill

01 Oct 2015

Year-end trading update

03 Sep 2015

Cancer research collaboration with Horizon Discovery Group plc

13 Jul 2015

Chancellor visits Redx labs

07 Jul 2015

LSE visit to Alderley Park site

22 Jun 2015

Interim Results For The Six Months Ended 31 March 2015

02 Jun 2015

Discovery of breakthrough MRSA compound

26 May 2015

Redx announces second drug development candidate

14 May 2015

Launch of third subsidiary, Redx Immunology Limited

11 May 2015

Redx reaches pre-clinical proof of concept with Oncology lead

05 Feb 2015

Redx Pharma featured in BBC Report on drug-resistant infections

11 Dec 2014

Redx features at key AMR Review

18 Nov 2014

European Antibiotic Awareness Day 2014

18 Nov 2014

Antibiotic Guardian – European Antibiotic Awareness Day

05 Nov 2014

Redx joins call to discover new antibiotics to stop global crisis

15 Oct 2014

Redx Pharma focuses on human health with agrichem deal

12 Sep 2014

Redx Pharma strengthens senior team

03 Sep 2014

Redx Pharma and AstraZeneca agree research collaboration targeting genetic drivers of tumour growth

01 Sep 2014

Redx Pharma appoints new chairman

20 Jun 2014

International Festival For Business 2014

06 Mar 2014

Redx Pharma and Pierre Fabre collaborate in the promising field of Onco-Dermatology

12 Feb 2014

€85 million European program targets novel antibiotics

30 Nov 2013

Redx Pharma addresses flagship antibiotic conference

29 Nov 2013

Redx Pharma named Bionow Company of the Year 2013

26 Nov 2013

Redx Pharma co-sponsors BioInfect 2013

07 Nov 2013

Redx agrees pioneering MRSA deal with NHS

14 Oct 2013

Health leaders gather to tackle ‘Antibiotic Apocalypse’

11 Oct 2013

Redx CEO scoops business leadership award

10 Sep 2013

BIA welcomes the publication of the UK government antimicrobial resistance strategy (AMR) that drives to put the challenge of AMR on the global agenda

29 Jul 2013

Redx Oncology enters agreement to support Liverpool tissue bank

12 Jul 2013

RGF backing for proposed Redx Metabolic venture

14 Jun 2013

Knowledge Business of the Year 2013

07 May 2013

Redx Pharma opens £10.5 million R&D centre at Alderley Park

02 May 2013

Redx Pharma and Pharmascience enter into license agreement for cFMS cancer program

13 Mar 2013

Antibiotic Resistance – Dr Neil Murray, CEO Redx Pharma

14 Jan 2013

Redx Oncology staff dig deep to raise funds for Liverpool Cancer Research UK Centre

02 Jan 2013

Redx Oncology continues to experience dramatic growth

Redx will have attendees at the following conferences:

10/03/2019 to 15/03/2019
Location: Whistler Conference Centre, Whistler, British Columbia, Canada

Keystone Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit

25/03/2019 to 27/03/2019
Location: Messe Wien Exhibition and Congress Center, Vienna, Austria

Bio-Europe Spring

29/03/2019 to 03/04/2019
Location: Georgia World Congress Center Atlanta, Georgia, USA

AACR Annual Meeting 2019

30/04/2019 to 01/05/2019
Location: etc.venues 155 Bishopsgate, London, UK

BioTrinity 2019

17/05/2019 to 22/05/2019
Location: Dallas, Texas, US

ATS 2019

31/05/2019 to 04/06/2019
Location: McCormick Place, Chicago, Illinois, US

ASCO 2019

03/06/2019 to 06/06/2019
Location: Philadelphia, PA, US

BIO 2019

22/06/2019 to 25/06/2019
Location: Hilton Boston Logan Airport, Boston, US

NASH Summit 2019

24/06/2019 to 25/06/2019
Location: Chesham, UK

BIA UK CEO and Investor Forum 2019

24/06/2019 to 25/06/2019
Location: Boston, US

GI Inflammatory Diseases Summit (GIIDS) 2019